Biotech Values

[masterlongevity]

agree I think elan is pretty fairly valued at $3-$4 Billion. Of course, if bapineuzumab works, then that value could triple. i don't see anything too interesting in their pipeline besides bapineuzumab, and since the ph 2 failed, it is very risky